[18F]-fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer

Journal of Surgical Oncology

Volumn 102, Issue 2, 2010, Pages 135-140

  Vallbohmer D ^a   Holscher A H ^a   Schneider, P M ^a,b   Schmidt, M ^a   Dietlein, M ^a   Bollschweiler, E ^a   Baldus, S ^c   Alakus, H ^a   Brabender, J ^a   Metzger, R ^a   Monig S P ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Gastric cancer; Neoadjuvant therapy; PET; Response assessment

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; ANTINEOPLASTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; GASTRECTOMY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL METHOD; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; STOMACH CANCER; TREATMENT RESPONSE; TUMOR CELL; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR REGRESSION; ADENOCARCINOMA; ADJUVANT THERAPY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSPECTIVE STUDY; SCINTISCANNING; STOMACH TUMOR;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; FLUORODEOXYGLUCOSE F18; FLUOROURACIL; GASTRECTOMY; HUMANS; KAPLAN-MEIERS ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; STOMACH NEOPLASMS;

EID: 77955121698     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21592     Document Type: Article

References (20)

1. Ott K, Sendler A, Becker K, et al.: Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: A prospective phase II study. Gastric Cancer 2003; 6:159-167. (Pubitemid 37221566)
2. Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
3. Boige V, Pignon J, Saint-Aubert B, et al.: Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol 2007;
4. (ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 4510).
5. Ott K, Fink U, Becker K, et al.: Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: Results of a prospective trial. J Clin Oncol 2003;21: 4604-4610.
6. Di Fabio F, Pinto C, Rojas Llimpe FL, et al.: The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab. Gastric Cancer 2007;10:221-227.
7. UICC. Sobin LH, Wittekind C, editors. TNM classification of malignant tumours, 6th edition. NewYork: Wiley-Liss; 2002.
8. Schneider PM, Baldus SE, Metzger R, et al.: Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: Implications for response classification. Ann Surg 2005;242:684-692. (Pubitemid 41567124)
9. Baldus SE, Mönig SP, Schröder W, et al.: Regression of oesophageal carcinomas after neoadjuvant radiochemotherapy: Criteria of the histopathological evaluation. Pathologe 2004;25: 421-427.
10. Schmidt M, Bollschweiler E, Dietlein M, et al.: Mean and maximum standardized uptake values in [18F]FDG-PET for assessment of histopathological response in oesophageal squamous cell carcinoma or adenocarcinoma after radiochemotherapy. Eur J Nucl Med Mol Imaging 2009;36:735-744.
11. Metz CE, Goodenough DJ, Rossmann K: Evaluation of receiver operating characteristic curve data in terms of information theory, with applications in radiography. Radiology 1973;109:297-303.
12. Bollschweiler E: Benefits and limitations of Kaplan-Meier calculations of survival chance in cancer surgery. Langenbeck's Arch Surg 2003;388:239-244.
13. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
14. Pocock SJ, Clayton TC, Altman DG: Survival plots of time-to-event outcomes in clinical trials: Good practice and pitfalls. Lancet 2002;359:1686-1689.
15. LeBlanc M, Jacobson J, Crowley J: Partitioning and peeling for constructing prognostic groups. Stat Methods Med Res 2002;11: 247-274.
16. Ott K, Herrmann K, Lordick F, et al.: Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomographyallows in vivo testing of chemosensitivity in gastric cancer: Long-term results of a prospective study. Clin Cancer Res 2008;14:2012-2018.
17. Wieder HA, Ott K, Lordick F, et al.: Prediction of tumor response by FDG-PET: Comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction. Eur J Nucl Med Mol Imaging 2007; 34:1925-1932.
18. Keyes JM, Jr.: SUV: Standard uptake or silly useless value? J Nucl Med 1995;36:1836-1839.
19. Lordick F, Ott K, Krause BJ, et al.: PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: The MUNICON phase II trial. Lancet Oncol 2007;8:797-805.
20. Lordick F, Ruers T, Aust DE, et al.: European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer. Eur J Cancer 2008;44:1807-1819.